Patent ID: 7736623

Claim:
A method for providing a cerebrospinal fluid (CSF) correction factor for CSF obtained from a patient suffering from a disease selected from the group consisting of mild cognitive impairment (MCI) and Alzheimer's Disease (AD) for at least one biomarker selected from the group consisting of an amyloid beta (Aβ) and a tau protein, comprising the steps of: (a) measuring levels of said at least one biomarker in samples of CSF obtained from the patient; (b) providing semi-automated measurements of the ventricular system by MRI scans using quantitative anatomical protocols; (c) correcting the concentration dilution level in the CSF of said at least one biomarker tested for in step (a) by using a computer algorithm that analyzes the absolute volume and the longitudinal changes in CSF measurements from the MRI scans obtained in step (b); and (d) providing the CSF correction factor for level of concentration of said at least one biomarker due to increased ventricular volume of CSF caused by the increase in ventricular size.